Innovations • Global Impact • In The News • Our People

AAHI Supports the UN's Sustainable Development Goals for 2030

Last week, the 2023 SDG Summit held in New York City marked the chronological half-way point to achieving the 17 goals set out to end poverty, protect the planet, and establish global peace and prosperity. We hold ourselves accountable and responsible for progress towards the five goals that AAHI supports by developing effective, sustainable, and cost-efficient health solutions.



Collaboration across communities.

Explore AAHI's different areas of impact.

Houston, Texas

AAHI's partners with Baylor College of Medicine to advance a novel Chagas Vaccine Candidate to Clinical Trials

Chagas disease is caused by a parasite found in the feces of an insect called triatomine, also known as the "kissing bug" - an insect in rural Latin America that resides in thatched roofs and mud walls. The kissing bug and Chagas are migrating north -- CDC now estimates more than 300,000 people live with the parasite in the United States. Chagas disease can develop silently for years before causing sever cardiac arrest or neurological damage and, in some cases, can be fatal. People in the United States are at risk for Chagas by receiving blood transfusions, and AAHI technology already contributes to a diagnostic test that helps screen the blood supply. The vaccine being tested combines Baylor's proprietary antigen with AAHI's GLA-SE adjuvant formulation.

Help us make impossible vaccines possible.


Dr. Christopher Fox presents at the September National Vaccine Advisory Committee (NVAC) meeting in Washington D.C.

By Christopher Fox, PhD, Senior Vice President, Formulations

NVAC Meeting

Last week, Dr. Fox joined Dr. Kentner Singleton at the National Institute of Health, and Dr. Prabhu Arunachalam at Stanford University to present on 'Adjuvants and Immune Response: Insights to Spur Innovation' at the NVAC meeting where the nation's most prominent vaccine experts meet to discuss presenting topics affecting the vaccine development, use, and distribution.

At this meeting, Dr. Fox highlighted the critical role that adjuvants can play in safely making future vaccines durable and protective and urged NVAC, which serves as a trusted advisor to US health policymakers, to seek opportunities to speed the development of novel adjuvanted vaccines.

View his presentation HERE.


Collaboration across communities.

Explore our different areas of impact.

Featured Post

AAHI launched its "Day in the Life" campaign in September, offering an exclusive glimpse into the daily routines and creative processes of our colleagues working to develop effective, sustainable, and accessible vaccine platform technologies. Each month, you will be introduced to a new colleague who will share their insights and inspiration that drives them today to shape the vaccine industry of tomorrow.

ICYMI- learn more about a day in the life of AAHI's Associate Manager of Facilities, Blaise Black.

Openings and Opportunities

Associate/Staff Scientist (RNA Vaccines)


The Associate/Staff Scientist will be responsible for directing the in vivo mouse immunology studies on the RNA team, providing support to conduct in vivo aspects of product stability and release testing studies for AAHI's Product Development and GMP teams as necessary.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.